Cheirif WO, Sáez OMM, Lammoglia OL

Language: Spanish
References: 46
Page: 305-313
PDF size: 153.26 Kb.

ABSTRACT

Topical corticosteroids are the most frequently used drugs in dermatology. Their success depends on the adequate evaluation of the patient, on an accurate clinical diagnosis, the site of the skin and the special response of the dermatoses. Topical corticosteroids are classified by their strength, the same molecule will have different strengh depending on the vehicle. There are many side effects which can be avoided if used correctly. Children are more prone to have systemic adverse effects to topically applied steroids. Skin adverse effects can occur with prolonged treatment. The most common local adverse effects include: atrophy of the skin, striae, rosacea, acne, perioral dermatitis, purpura, hypertrichosis, pigmentation, delayed wound healing, and exacerbation of skin infections. There are also systemic side effects like glaucoma and adrenal insufficiency but they are rare. We must be aware that many patients with steroid- responsive dermatoses remain under treated, and our role is to optimize patient outcomes while minimizing the risk of complications and side effects.

REFERENCES

1. Wilder, R., Cupps, T.R. y Balow, J.E., “Glucocorticoid therapy for immune- mediated diseases: basic and clinical correlates”, Ann Intern Med, 1993, 119: 1198-1208.

2. Sáez de Ocariz, M., “Los nuevos esteroides tópicos”, Dermatología Rev Mex, 2001, 45: 29-34.

3. Kumar Dey, V., “Misuse of topical corticosteroids: a clinical study of adverse effects”, Indian Dermatol Online J, 2014, 5: 436-440.

4. Johnson, R.B. y Lazarus, G.S., “Pulse therapy: therapeutic efficacy in the treatment of pyoderma gangrenosum”, Arch Dermatol, 1982, 118: 76-84.

5. Brazzini, B. y Pimpinelli, N., “New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use”, Am J Clin Dermatol, 2002, 3: 47-58.

6. Jackson, S., Gilchrist, H. y Nesbitt, L.T., “Update on the dermatologic use of systemic glucocorticosteroids”, Dermatol Ther, 2007, 20: 187-205.

7. Williams, L.C. y Nesbitt, L.T., Jr., “Update on systemic glucocorticosteroids in dermatology”, Dermatol Clin, 2001, 19: 63-77.

8. Drake, L.A. et al., “Guidelines of care for the use of topical glucocorticosteroids”, J Am Acad Dermatol, 1996, 35: 615-619.

9. Serrano, P., “Corticoides tópicos. Actualización”, Med Cutan Iber Lat Am, 2006, 34: 33-38.

10. Ballona, R. y Ballona, C., “Corticoides tópicos en pediatría: una puesta al día”, Dermatol Peruana, 2003, 13: 163-170.

11. Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Cupps, T.R. y Balow, J.E., “Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates”, Ann Intern Med, 1993, 119: 1198-1208.

12. Torrelo, A. y Pérez-Gala, S., “Uso de corticoides orales en dermatología pediátrica”, Dermatol Pediatr Lat, 2005, 3: 71-82.

13. Sáez de Ocariz, M., “Esteroides tópicos”, Dermatología Rev Mex, 1997, 41: 184-190.

14. Stoughton, R.B. y Wullich, K., “Relation of application time to bioactivity of a potent topical glucocorticoid formulation”, J Am Acad Dermatol, 1990, 22: 1038-1041.

15. Hughes, J. y Rustin, M., “Corticosteroids”, Clin Dermatol, 1997, 15: 715-721.

16. Wiedesberg, S., Leopold, C.L. y Guy, R.H., “Bioavailability and bioequivalence of topical glucocorticoids”, Eur J Pharm Biopharm, 2008, 68: 453-466

17. Nieman, L.K., “Consequences of systemic absorption of topical glucocorticoids”, J Am Acad Dermatol, 2010, 65: 250-252.

18. Ference, J.D. y Last, A.R., “Choosing topical corticosteroids”, Am Fam Physician, 2009, 79: 135-140.

19. Carlos, G., Uribe, P. y Fernández-Peñas, P., “Rational use of topical corticosteroids”, Aust Prescr, 2013, 36: 158-161.

20. Pershing, L.K., Silver, B.S., Krueger, G.G. et al., “Feasibility crf measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay”, Pharmacol Res, 1992, 9: 45-51.

21. Hengge, U.R., Ruzicka, T., Schwartz, R.A. y Cork, M.J., “Adverse effects of topical glucocorticosteroids”, J Am Acad Dermatol, 2006, 54: 1-15.

22. Feldmann, R.J. y Maibach, H.I., “Regional variation in percutane: ous penetration of 14c cortisol in man”, J Invest Dermatol, 1967, 48: 181-183.

23. Long, C.C. y Finaly, A.Y., “The finger-tip unit: a new practical measure”, Clin Exp Dermatol, 1991, 16: 444-447.

24. Enríquez Merino, J. y Caballero Centeno, A.M., “Opciones terapéuticas para cicatrices queloides e hipertróficas”, Rev Cent Dermatol Pascua, 2007, 16: 80-84.

25. Gupta, S. y Sharma, V.K., “Standard guidelines of care: keloids and hypertrophic scars”, Indian J Dermatol Venereol Leprol, 2011, 77: 94-100.

26. Du Vivier A., “Tachyphylaxis to topically applied steroids”, Arch Dermatol, 1976, 112: 1245.

27. Del Rosso, J. y Fallon Friedlander, S., “Corticosteroids: options in the era of steroid-sparing therapy”, J Am Acad Drmatol, 2005, 53: S50-58.

28. Korting, H.C., Kerscher, M.J. y Schafer-Koting, M., “Topical glucocorticoids with improved benefit/risk ratio: do they exist?”, J Am Acad Dermatol, 1992, 27: 87-92.

29. Kirby, J.D. y Munro, D.D., “Steroid-induced atrophy in animal and human models”, Br J Dermatol, 1976, 94: 111-119.

30. Barnes, L., Kaya, G. y Rollason, V., “Topical corticosteroid-induced skin atrophy: a comprehensive review”, Drug Saf, 2015, 38: 493-509.

31. Chen, A.Y.y Zirwas, M.J., “Steroid-induced rosacealike dermatitis: case report and review of the literature”, Cutis, 2009, 83 (4): 198-204.

32. Hafeez, Z.H., “Perioral dermatitis: an update”, Int J Dermatol, 2003, 42: 514-517.

33. Hameed, A.F., “Steroid dermatitis resembling rosacea: a clinical evaluation of 75 patients”, isrn Dermatol, 2013, 491376.

34. Ljubojeviae, S., Basta-Juzbasiae, A. y Lipozenèiae, J., “Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment”, J Eur Acad Dermatol Venereol, 2002, 16: 121-126.

35. Hajar, T., Leshman, Y., Hanifin, J.M., Nedorost, S.T., Lio, P., Saller, A.S. et al., “A systematic review of topical corticosteroid withdrawal (‘steroid addiction’) in patients with atopic dermatitis and other dermatoses”, J Am Acad Dermatol, 2015, 72: 541-549.

36. Davis, M.D.P., el-Azhary, R.A. y Farmer, S.A., “Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo Clinic”, J Am Acad Dermatol, 2007, 56: 921.

37. Sandoval LF, Davis S, Feldman SR. “Dermatologists´ knowledge of and Preferences regarding topical steroids”. J Drugs Dermatol 2013;12:786-789.

38. Isaksson, M. et al., “Patch testing with corticosteroid mixes in Europe. A multicentre study of the eecdrg”, Contact Dermatitis, 2000, 42: 27-35.

39. Lutz, M.E., el-Azhary, R.A., Gibson, L.E. y Fransway, A.F., “Contact hypersensitivity to tixocortol pivalate”, J Am Acad Dermatol, 1998, 38: 691-695.

40. Martínez Martínez, M.L., Pérez García, L.J., Escario Travesedo, E., Rodríguez Vázquez, M. y Fernández Aragón, G., “Dermatitis alérgica de contacto por corticoides”, Rev Clin Med Fam, 2009, 2: 438-441.

41. Coopman, S., Degreef, H. y Dooms-Goossens, A., “Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids”, Br J Dermatol, 1989, 121: 27-34.

42. Walsh, P., Aeling, J.L., Huff, L. y Weston, W.L., “Hypothalamus-pituitary- adrenal axis suppression by superpotent topical steroids”, J Am Acad Dermatol, 1993, 29: 501.

43. Cook, L.J., Freinke, R.K., Zugerman, C., Levin, D.L. y Radtke, R., “Latrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria”, J Am Acad Dermatol, 1982, 6 (6): 1054-1060.

44. Haeck, I.M., Rowen, T.J., Timmer-de Mik, L., De Bruin-Weller, M.S., Bruijnzeel-Koomen, C.A., “Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts”, J Am Acad Dermatol, 2011, 64: 275-281.

45. Ballona, R., “‘Soft steroids’ o corticoides suaves en dermatología pediátrica”, Dermatol Pediatr Lat, 2005, 3: 150-157.

46. Lester, R.S., “Corticosteroids”, Clin Dermatol, 1989, 7: 80-97.